Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
<strong>Introduction </strong>The reduction of the risk of asthma attacks is a major goal of guidelines. The fact that type-2 inflammatory biomarkers identify a higher risk, anti-inflammatory responsive phenotype is potentially relevant to this goal. We aim to quantify the relation betwe...
Autors principals: | Couillard, S, Steyerberg, E, Beasley, R, Pavord, I |
---|---|
Format: | Journal article |
Publicat: |
BMJ Publishing Group
2022
|
Ítems similars
-
Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
per: Richard Beasley, et al.
Publicat: (2022-04-01) -
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
per: Couillard, S, et al.
Publicat: (2021) -
Fractional exhaled nitric oxide non-suppression in asthma
per: Couillard Castonguay, S
Publicat: (2021) -
Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
per: Shrimanker, R, et al.
Publicat: (2018) -
Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
per: Price, D, et al.
Publicat: (2019)